RT Journal Article
SR Electronic
T1 Development and Validation of a Survival Calculator for Hospitalized Patients with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.22.20075416
DO 10.1101/2020.04.22.20075416
A1 Levy, Todd J.
A1 Richardson, Safiya
A1 Coppa, Kevin
A1 Barnaby, Douglas P.
A1 McGinn, Thomas
A1 Becker, Lance B.
A1 Davidson, Karina W.
A1 Cohen, Stuart L.
A1 Hirsch, Jamie S.
A1 Zanos, Theodoros P.
A1 ,
A1 Bodenstein, Hannah
A1 Debnath, Shubham
A1 Dominello, Andrew J.
A1 Falzon, Louise
A1 Gitman, Michael
A1 Goldstein, Jay M.
A1 Herron, Crystal
A1 Kim, Eun-Ji
A1 Lau, Lawrence
A1 Lockerman, Zachary S.
A1 Makhnevich, Alexander
A1 Mogavero, Jazmin N.
A1 Molmenti, Ernesto P.
A1 Paradis, Marc d.
A1 Tóth, Viktor
YR 2020
UL http://medrxiv.org/content/early/2020/06/02/2020.04.22.20075416.abstract
AB Background Chinese studies reported predictors of severe disease and mortality associated with coronavirus disease 2019 (COVID-19). A generalizable and simple survival calculator based on data from US patients hospitalized with COVID-19 has not yet been introduced.Objective Develop and validate a clinical tool to predict 7-day survival in patients hospitalized with COVID-19.Design Retrospective and prospective cohort study.Setting Thirteen acute care hospitals in the New York City area.Participants Adult patients hospitalized with a confirmed diagnosis of COVID-19. The development and internal validation cohort included patients hospitalized between March 1 and May 6, 2020. The external validation cohort included patients hospitalized between March 1 and May 5, 2020.Measurements Demographic, laboratory, clinical, and outcome data were extracted from the electronic health record. Optimal predictors and performance were identified using least absolute shrinkage and selection operator (LASSO) regression with receiver operating characteristic curves and measurements of area under the curve (AUC).Results The development and internal validation cohort included 11□095 patients with a median age of 65 years [interquartile range (IQR) 54-77]. Overall 7-day survival was 89%. Serum blood urea nitrogen, age, absolute neutrophil count, red cell distribution width, oxygen saturation, and serum sodium were identified as the 6 optimal of 42 possible predictors of survival. These factors constitute the NOCOS (Northwell COVID-19 Survival) Calculator. Performance in the internal validation, prospective validation, and external validation were marked by AUCs of 0.86, 0.82, and 0.82, respectively.Limitations All participants were hospitalized within the New York City area.Conclusions The NOCOS Calculator uses 6 factors routinely available at hospital admission to predict 7-day survival for patients hospitalized with COVID-19. The calculator is publicly available at https://feinstein.northwell.edu/NOCOS.Trial registration N/AFunding Source This work was supported by grants R24AG064191 from the National Institute on Aging, R01LM012836 from the National Library of Medicine, and K23HL145114 from the National Heart Lung and Blood Institute.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants R24AG064191 from the National Institute on Aging, R01LM012836 from the National Library of Medicine, and K23HL145114 from the National Heart Lung and Blood Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards at Northwell Health and Maimonides Medical Center as minimal-risk research that used data collected for routine clinical practice, and as such, waived the requirement for informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from COVID19@northwell.edu. The data are not publicly available due to restrictions as it could compromise the privacy of research participants. http://feinstein.northwell.edu/nocos